Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
397 hedge funds and large institutions have $3.39B invested in Catalyst Pharmaceutical in 2026 Q2 according to their latest regulatory filings, with 99 funds opening new positions, 117 increasing their positions, 123 reducing their positions, and 82 closing their positions.
31% more capital inflows, than outflows
Capital inflows: $904M | Capital outflows: $690M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 82
4% more funds holding
Funds holding: 383 → 397 (+14)
2.41% more ownership
Funds ownership: 85.68% → 88.08% (+2.4%)
5% less repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 123
43% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $2.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Glazer Capital LLC
New York
|
+$106M |
| 2 |
HBK Investments
Dallas,
Texas
|
+$83.2M |
| 3 |
JP Morgan Chase
New York
|
+$79.8M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$54.4M |
| 5 |
Nexpoint Asset Management
Dallas,
Texas
|
+$47.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$97.6M |
| 2 |
Royce & Associates
New York
|
-$51.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$50.9M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.9M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$21.7M |
CPRX Hedge Fund Activity: Q2 2026 in Review
397 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2026, worth a combined $3.39B — up 31% from $2.59B a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new CPRX positions and 82 closed out — a net gain of 17 holders — while 117 added to existing stakes and 123 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $106M. The largest seller was Deerfield Management, exiting entirely with an estimated $97.6M sold.
- 397 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2026, up from 383 in Q1 2026.
- Funds reported $3.39B of Catalyst Pharmaceutical stock for Q2 2026, up 31% quarter-over-quarter.
- 99 funds opened new Catalyst Pharmaceutical positions in Q2 2026 and 82 closed out, a net change of +17 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2026 was Glazer Capital LLC, an estimated $106M added.
- The largest Catalyst Pharmaceutical seller in Q2 2026 was Deerfield Management, an estimated $97.6M sold.
Based on aggregated 13F filings for Q2 2026.